Current Event 2022

WEEK OF OCTOBER 31, 2022

The Future of Precision and Predictive Health Care

Japan Healthcare Week, featuring Conference Events in Tokyo (Oct. 31) and Awajishima (Nov. 2)

Upcoming Event on October 31st, 2022

— The Future of Precision and Predictive Healthcare —

Japan Week 2022 | Meet American and Japanese Companies

WHEN

Tokyo Executive Symposium
Oct 31, 2022
1:00–5:00 PM (JT)

Followed by Networking Reception

WHERE

Tokyo Executive Symposium:

Nihonbashi Life Science Hub (Link)

KEYNOTE
Andrew Cleeland

Chief Executive Officer,
Fogarty Innovation

Andrew Cleeland is the CEO of Fogarty Innovationseasoned executive with more than 30 years of experience in the medical device industry, he has held key leadership positions in organizations ranging from earlystage startups to large multinationals.

Bio

— HEALTHCARE SYMPOSIUM AGENDA —
Tokyo, Monday, October 31st, 2022
*Invitation Only

12:30 P.M. – 1:00 P.M.

REGISTRATION

1:00 P.M. – 1:15 P.M.

OPENING OF SYMPOSIUM

1:15 P.M. – 2:05 P.M.

KEYNOTE SPEECH: INNOVATION FOR THE FUTURE OF PREDICTIVE HEALTHCARE

Followed by Q&A session moderated by Dr. Fumiaki Ikeno

Andrew Cleeland is the CEO of Fogarty Innovation. A seasoned executive with more than 30 years of experience in the medical device industry, he has held key leadership positions in organizations ranging from early–stage start–ups to large multinationals.

Bio

2:05 P.M. – 2:55 P.M.

SESSION 1: PRECISION, PREDICTIVE, & PROACTIVE HEALTHCARE – BETTER OUTCOMES, LOWER COSTS, AND HIGHER PATIENT SATISFACTION

After graduating from Jichi Medical University, he began practicing general medicine in the rural areas of Japan. Fumiaki joined the Department of Cardiovascular Medicine at Stanford University in 2001, and was closely involved with the R&D, animal studies, and clinical studies of many medical device startups. He is also actively involved in projects with the US and Japanese regulatory agencies working to create an effective cross-border medical device eco-system. Fumiaki has also been an advisory faculty for the Stanford Biodesign Program since 2014. He is deeply involved with the development of the Japan Biodesign Program and is working diligently to establish a Silicon Valley-like medical device eco-system in Japan.

Andrew Cleeland is the CEO of Fogarty Innovation. A seasoned executive with more than 30 years of experience in the medical device industry, he has held key leadership positions in organizations ranging from early–stage start–ups to large multinationals.

Bio

Mika is a commercialization executive with extensive leadership experience in conceiving, planning, and launching disruptive medical technologies in 50 markets across North America, EMEA, Asia-Pacific, and Latin America. She has an exceptional track record of leading businesses from inception to across different clinical segments, including cardiovascular, fertility, and oncology.

Bio

Ryan was trained in genetics and cell biology at the University of California at Davis. Since 1988 he has worked in several biotechnology companies and as an independent biotech consultant focused on adding value to early stage therapeutic and technology efforts. Early in his career Ryan worked in teams that applied cutting edge genetic engineering technologies to advance the development of gene therapy and cellular therapeutics.

Bio

2:55 P.M. – 3:05 P.M.

BREAK

3:05 P.M. – 3:55 P.M.

SESSION 2: PREDICTIVE HEALTHCARE TARGETS

Harry started his career in Japan at Citizen Watch Co. and was soon after transferred to Dubai, New Jersey, and Los Angeles to oversee product development in international markets. Harry left the company as CFO of the US subsidiary, then started a medical device sales company in California as a joint venture with a Japanese medical device company. He struggled with the US medical device business initially but found success after acquiring a small US manufacturer and expanding the business. He exported the products to 25 countries from the United States.

Bio

Partha Ray is a mission-driven medtech innovation leader with over 25 years of deal & operating experience at leading global organizations. Partha has launched products and closed deals which benefit over 9M patients and generate over $20B/yr in revenues today.

Bio

Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. Elton represents both public and private enterprises as their outside general counsel and serves as a key strategic advisor from their inception throughout their life cycle. He advises on complex venture capital and corporate finance transactions, corporate law and governance, mergers and acquisitions, and public offerings. 

Bio

Dr. Burnett is a veteran in the medical device industry having founded many successful companies at various stages. During his undergraduate career at the University of Pennsylvania, he focused on bioengineering and spent a year at the Food and Drug Administration both testing devices and writing congressional reports on the current state-of-the-art devices.

Bio

3:55 P.M. – 5:15 P.M.

PRIVATE EARLY STAGE AND PRIVATE COMPANY PRESENTATIONS

Martin Williams is a seasoned therapeutics developer with experience in multiple disease areas from start-up to large cap organizations. Previously, he held roles leading global product management for neurovascular devices and designing neurological diagnostics devices as an engineer. He was on the founding team and is currently leading business development efforts at Cognito Therapeutics, a pioneer in disease-modifying therapeutic interventions for neurodegenerative diseases entering Phase 3 studies with its novel approach to Alzheimer’s disease. 

Bio

Founder and CEO of EchoPixel, a startup company pioneering medical imaging VR/AR solutions that are defining a new visualization paradigm Holographic Therapy Guidance (HTG), which allows doctors to perform minimally invasive surgeries using a digital twin of the patient that they experience as a hologram.

Bio

5:15 P.M.

KEYNOTE & CLOSING REMARKS

5:15 P.M. – 6:30 P.M.

RECEPTION & SOCIAL NETWORKING